Issue Date: August 29, 2011
More Hits Tallied For Cardiac Amyloidosis
Although FDA has yet to approve any drugs for the treatment of transthyretin-based cardiac amyloidosis, a disease caused by aggregation of proteins in the heart, a study adds more candidates to the list of possibilities (Sci. Transl. Med., DOI: 10.1126/scitranslmed.3002473). Transthyretin is a tetrameric protein that transports the hormone thyroxine throughout the body. When the protein becomes unstable, particularly because of a mutation, it aggregates and can cause heart arrhythmia and failure. Current transthyretin-stabilizing . . .
To view the rest of this content, please log in with your ACS ID.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society